Peters S, Dziadziuszko R, Morabito A, Felip E, et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med 2022;28:1831-1839.
PMID: 35995953